Everolimus combined with gefitinib in patients with metastatic castration‐resistant prostate cancer: Phase 1/2 results and signaling pathway implications

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|121|21|3853-3861

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.21, 2015-11, pp. : 3853-3861

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration‐resistant prostate cancer

By  

BJU INTERNATIONAL, Vol. 118, Iss. 4, 2016-10 ,pp. : 590-597

John Wiley & Sons Inc

Access to resources Recommend Favorite

Systemic immune‐inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration‐resistant prostate cancer patients

By  

THE PROSTATE, Vol. 78, Iss. 4, 2018-03 ,pp. : 250-256

John Wiley & Sons Inc

Access to resources Recommend Favorite

Is prostate cancer changing?: Evolving patterns of metastatic castration‐resistant prostate cancer

By  

CANCER, Vol. 120, Iss. 6, 2014-03 ,pp. : 833-839

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase I study of TRC105 anti‐endoglin (CD105) antibody in metastatic castration‐resistant prostate cancer

By  

BJU INTERNATIONAL, Vol. 116, Iss. 4, 2015-10 ,pp. : 546-555

John Wiley & Sons Inc

Access to resources Recommend Favorite

Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration‐resistant prostate cancer

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 12, 2015-12 ,pp. : 1406-1414

John Wiley & Sons Inc

Access to resources Recommend Favorite